RA
AVDL

Royce & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Royce & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,460
Closed -$278K – 790
2025
Q1 		$278K Hold
35,460
– – ﹤0.01% 760
2024
Q4 		$373K Hold
35,460
– – ﹤0.01% 777
2024
Q3 		$465K Hold
35,460
– – ﹤0.01% 805
2024
Q2 		$499K Sell
35,460
-13,102
-27% -$214K ﹤0.01% 790
2024
Q1 		$820K Buy
48,562
+27,581
+131% +$411K 0.01% 746
2023
Q4 		$296K Buy
+20,981
New +$246K ﹤0.01% 825

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $2.17B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return